MedTech company specialising in non-invasive MRI-based liver and heart iron assessment and clinical trial imaging services
No capital raise or buyback data
| Event | Type | Confidence | Impact | Date | Status |
|---|
Historical delivery and spending consistency. Data is limited for recently added companies.
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
| Sun Pharma CRO contract milestones ($13.775M, 24-month)open_in_new The Sun Pharma CRO contract is progressing as expected, with revenue from clinical trial services contributing to the company's improved financial performance and higher-margin service offerings in FY26. | commercial milestone | Confirmed | arrow_upwardHigh | 4 May 2026 | Completed |